Biodegradable stents : "fulfilling the mission and stepping away".

In 458 BC, a prominent Roman leader named Lucius Quintius Cincinnatus was unique in his behavior. Cincinnatus served his country when he was needed and, after fulfilling his duty, he returned to his private life.1 We now see a new medical device, a biodegradable stent, that mimics this historical figure. The 2 main functions of a stent, treatment of dissection and prevention of restenosis, refer to 2 events that occur and progress in a set frame of time. Coronary dissections are effectively contained by stent insertion and undergo a healing process, with the majority of cardiac events occurring in the first 6 months.2 In-stent restenosis also occurs within the first 6 months.3 Therefore, a permanent prosthesis that is in place beyond this initial period has no clear function. Besides lacking a well-defined function, are there any negative aspects related to the presence of a permanent coronary implant? Zidar et al4 stated that one of the main reasons to develop a biodegradable stent was the short-term need for a stent and the potential long-term complications of metal stents. Kimura et al3 demonstrated, with an extended angiographic follow-up of 3 years, that the presence of a metallic stent does not seem to be associated with lesion progression or accelerated atherosclerosis of the treated site after 6 months. In fact, late improvement in luminal diameter seems to occur between 6 months and 3 years. The Belgian Netherlands Stent Study (BENESTENT I) recently extended its follow-up to 5 years and demonstrated a sustained and persistent benefit of the stent.5 If no demonstrable complications exist with a permanent intracoronary implant, can the question be turned around by asking, “What are the benefits of not having a permanent coronary implant?” Two answers can be given. 1. Coronary stenting freezes recoil, …

[1]  R Waksman,et al.  Procedural results and late clinical outcomes after placement of three or more stents in single coronary lesions. , 1998, Circulation.

[2]  P Hall,et al.  Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. , 1995, Circulation.

[3]  Keiji Igaki,et al.  A Biodegradable Poly‐l‐lactic Acid Coronary Stent in the Porcine Coronary Artery , 1999 .

[4]  A. Cribier,et al.  Intracoronary stent implantation without ultrasound guidance and with replacement of conventional anticoagulation by antiplatelet therapy. 30-day clinical outcome of the French Multicenter Registry. , 1996, Circulation.

[5]  H Yokoi,et al.  Three-year follow-up after implantation of metallic coronary-artery stents. , 1996, The New England journal of medicine.

[6]  M. Leon,et al.  Chronic arterial responses to stent implantation: a serial intravascular ultrasound analysis of Palmaz-Schatz stents in native coronary arteries. , 1996, Journal of the American College of Cardiology.

[7]  J C Greenfield,et al.  Interventional cardiac catheterization at Duke Medical Center. , 1988, The American journal of cardiology.

[8]  H. Uehata,et al.  Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. , 2000, Circulation.

[9]  Eric J. Topol,et al.  Textbook of Interventional Cardiology , 1999 .

[10]  E. Topol,et al.  Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. , 1996, Circulation.

[11]  J. Sixma,et al.  Thrombogenicity of the human arterial wall after interventional thermal injury. , 1996, Journal of vascular research.

[12]  M. Hadamitzky,et al.  A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. , 1996, The New England journal of medicine.

[13]  E J Topol,et al.  Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. , 1997, Journal of the American College of Cardiology.

[14]  M. Leon,et al.  Dose-dependent smooth muscle cell proliferation induced by thermal injury with pulsed infrared lasers , 1992, 1992 14th Annual International Conference of the IEEE Engineering in Medicine and Biology Society.

[15]  H Shimokawa,et al.  Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo. , 1998, Journal of the American College of Cardiology.

[16]  A. Kastrati,et al.  Four‐Year Experience With Palmaz‐Schatz Stenting in Coronary Angioplasty Complicated by Dissection With Threatened or Present Vessel Closure , 1994, Circulation.